Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer

2 Apr 2025

Abstract excerpt

Background Triple-negative breast cancer (TNBC) is an aggressive sub-type of breast cancer that is associated with higher rates of recurrent disease. Chemotherapy with an anthracycline is an integral part of curative therapy but resistance remains a clinical problem. Cellular senescence is a terminal cell fate that has been observed in models of doxorubicin resistance. Identifying novel combinations with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Retinoids in leukemia and cellular processes
Share to Telomeres, Telomerase, and Senescence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40242242
DOI: 10.3389/fonc.2025.1549282

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancerPMID 40242242Read ↗

Sorafenib, rapamycin, and venetoclax attenuate doxorubicin-induced senescence and promote apoptosis in HCT116 cellsSemantic proximity Read ↗

Senescence-Induced Chemoresistance in Triple Negative Breast Cancer and Evolution-Based Treatment StrategiesSemantic proximity Read ↗

Thymoquinone Alterations of the Apoptotic Gene Expressions and Cell Cycle Arrest in Genetically Distinct Triple-Negative Breast Cancer CellsSemantic proximity Read ↗

Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cellsSemantic proximity Read ↗

Therapy-induced senescence in breast cancer: an overviewSemantic proximity Read ↗

Disrupted Lipid Metabolism, Cytokine Signaling, and Dormancy: Hallmarks of Doxorubicin-Resistant Triple-Negative Breast Cancer ModelsSemantic proximity Read ↗

Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast CancerSemantic proximity Read ↗

Novel senolytic and senescence-suppressing compounds overcome senescence-driven chemoresistance in NSCLCSemantic proximity Read ↗

Flavopiridol inhibits FOXM1/NF-kB and KRAS/MAPK signaling and DNA repair mechanims and Sensitizes Triple-Negative Breast Cancer Cells to Doxorubicin theSemantic proximity Read ↗

Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatmentSemantic proximity Read ↗

Berberine Impairs the Survival of Triple Negative Breast Cancer Cells: Cellular and Molecular AnalysesSemantic proximity Read ↗

A novel curcumin-like dienone induces apoptosis in triple-negative breast cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.